<DOC>
	<DOCNO>NCT00947531</DOCNO>
	<brief_summary>This clinical trial perform assess clinical efficacy safety two 4 week treatment course daily intravenous administration Cerebrolysin ( 20mL [ milliliter ] IV [ intravenous ] per day ) . The study perform prospective , randomised , double-blind , placebo-controlled , parallel group , multicentre study 2 study group . Group 1 : 20 mL Cerebrolysin 100 mg ( milligram ) acetylsalicylic acid Group 2 : Placebo ( 0.9 % NaCl [ sodium chloride ] ) 100 mg acetylsalicylic acid The study drug give daily intravenous infusion ( 20ml 250ml saline solution ) 4 week five consecutive day per week . This treatment regimen repeat two-month treatment-free interval . Acetylsalicylic acid give orally , daily throughout study duration 24 week . Altogether five clinical evaluation visit Baseline ( day 0 ) week 4 , 12 , 16 , 24 necessary .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety Efficacy 20 ml Cerebrolysin Patients With Vascular Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>Men postmenopausal woman 50 85 year Clinical diagnosis vascular dementia accord NINDSAIREN criterion CT MRI result compatible clinical diagnosis MMSE score 10 24 , inclusive Modified Hachinski Ischemic Score &gt; 4 Hamilton Depression Scale score less equal 15 Adequate visual auditory acuity allow neuropsychological testing Informed consent give patient and/or nextofkin Gastric ulcer associate intolerance acetylsalicylic acid treatment Severe psychotic feature , schizophrenia , depression , agitation behavioral problem within last three month could lead difficulty comply protocol Any severe systemic illness unstable medical condition could lead difficulty comply protocol significantly limit life span . Patients investigator 's opinion , would comply study procedure Any significant neurological disease vascular dementia , Parkinson 's disease , epilepsy , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis History alcohol substance abuse dependence within past two year Patients history systemic cancer within past two year Severe congestive heart failure malignant , uncontrollable hypertension Participation clinical trial investigational drug past four week</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>